摘要
[目的]探讨胫骨横向骨搬移(tibial transverse transport,TTT)治疗合并脓毒症/脓毒症休克的重度糖尿病足的疗效。[方法]回顾性分析2015年4月—2020年8月本院治疗的合并脓毒症/脓毒症休克的重度糖尿病足77例患者的临床资料。首先所有患者均接受矫正休克,改善全身情况,应用敏感抗生素和局部清创等治疗;然后根据医患沟通结果,45例行TTT治疗,32例行传统治疗。比较两组临床及辅助检查结果。[结果]TTT组的住院时间[(21.8±7.6)d vs(28.6±12.0)d,P=0.007]、清创次数[(2.1±0.5)次vs(3.5±1.0)次,P<0.001]、换药次数[(19.7±7.5)次vs(25.1±11.1)次,P=0.013]、出院时创面面积[(68.2±27.4)cm^(2)vs(105.2±20.5)cm^(2),P=0.003]、住院期间截肢率[8(17.8%)vs 15(46.9%),P=0.006]和死亡率[1(2.2%)vs 7(21.9%),P=0.005]均显著低于传统组。随访时间1~72个月,平均(20.4±15.8)个月。末次随访时足保留者死亡例数TTT组为8(22.2%)例,传统组为6(60.0%)例,差异有统计学意义(P=0.022)。保肢成功例数TTT组为26(72.2%)例,传统组为0(0%)例,差异有统计学意义(P<0.001)。截止末次随访时存活者TTT组的PCS评分[(43.5±3.4)vs(40.6±2.1),P=0.043]和MCS评分[(46.4±3.6)vs(36.5±2.4),P<0.001]均显著优于传统组。随着时间的推移,两组的PCS评分和MCS评分均显著优于治疗前(P<0.05)。辅助检查方面,随着时间推移,两组的WBC、PCT、CRP、ESR、IL-6均显著降低(P<0.05)。出院时,TTT组保肢者的WBC、PCT、CRP、ESR、IL-6均显著低于传统组(P<0.05)。TTT组出院时的CTA血管显像显著优于传统组(P<0.05),末次随访时TTT组的CTA血管显像显著优于出院时(P<0.05)。[结论]与传统治疗方法相比,TTT治疗合并脓毒症或脓毒症休克的重度糖尿病足可明显提高创面愈合率,降低截肢率和死亡率,缓解疼痛,改善患肢功能,提高生活质量。
[Objective]To explore the clinical outcomes of tibia transverse transport(TTT)for diabetic foot accompanied with sepsis or septic shock.[Methods]A retrospective study was conducted on 77 patients who received treatments for severe diabetic foot complicated with sepsis or septic shock in our hospital from April 2015 to August 2020.First of all,all the patients received treatments of anti-shock,im-provement of general condition with sensitive antibiotics,and local debridement.Subsequently,45 patients were treated with TTT,while the remaining 32 patients were with traditional treatment according to the doctor-patient communication.The documents regarding clinical con-dition and auxiliary examination were compared between the two groups.[Results]The TTT group proved significantly superior to the tradi-tional group in terms of hospital stay[(21.8±7.6)days vs(28.6±12.0)days,P=0.007],debridement times[(2.1±0.5)times vs(3.5±1.0)times,P<0.001],dressing change times[(19.7±7.5)times vs(25.1±11.1)times,P=0.013],wound area at discharge[(68.2±27.4)cm^(2)vs(105.2±20.5)cm^(2),P=0.003],amputation rate during hospitalization[8(17.8%)vs 15(46.9%),P=0.006]and mortality in hospital[1(2.2%)vs 7(21.9%),P=0.005].The follow-up period was 1~72 months with an average of(20.4±15.8)months.At the final follow-up,8(22.2%)patients in the TTT group and 6(60%)patients in the traditional group died;the difference was statistically significant(P=0.022).And 26(72.2%)patients in the TTT group while no patients(0%)in the traditional group were salvageable;the difference was statistically significant(P<0.001).At the final follow-up,PCS score[(43.5±3.4)vs(40.6±2.1),P=0.043]and MCS score[(46.4±3.6)vs(36.5±2.4),P<0.001]in the TTT group were sig-nificantly higher than those in the traditional group.As time went by,PCS score and MCS score in both groups were significantly higher than before treatment(P<0.05).As for auxiliary examination,WBC,PCT,CRP,ESR,and IL-6 in both groups were significantly decreased over time(P<0.05).At discharge,WBC,PCT,CRP,ESR,and IL-6 of limb salvage patients in TTT group were significantly lower than those in traditional group(P<0.05).The CTA angiography in the TTT group at discharge was significantly better than that in the traditional group(P<0.05),and the CTA angiography in the TTT group at the last follow-up was significantly better than that at discharge(P<0.05).[Conclusion]Compared with traditional therapy,TTT treatment for severe diabetic foot complicated with sepsis or septic shock can significantly improve the wound healing rate,reduce the amputation rate and mortality,relieve pain,improve the function of affected limb,and improve the quality of life.
作者
苏永锋
丁毅
赵永鑫
刘杰
陈业平
曾道福
韦桂政
廖志东
花奇凯
陈炎
SU Yong-feng;DING Yi;ZHAO Yong-xin;LIU Jie;CHEN Yeping;ZENG Dao-fu;WEI Gui-zheng;LIAO Zhi-dong;HUA Qi-kai;CHEN Yan(Department of Orthopedics,The First Affiliated Hospital,Guangxi Medical University,Nanning 530021,China;Provincial Collaborative Innovation Center for Regenerative Medicine and Development and Application of Medical Biological Resources,Guangxi Medical University,Nanning 530021,China;Diabetic Foot and LimbPreservation Engineering Research Center of Guangxi Zhuang Autonomous Region,Nanning 530021,China)
出处
《中国矫形外科杂志》
CAS
CSCD
北大核心
2023年第19期1735-1741,共7页
Orthopedic Journal of China
基金
国家自然科学基金项目(编号:82060406,81601930,82260448)
中国博士后科学基金项目(编号:2019M650235)
广西壮族自治区自然科学基金项目(编号:2017GXNSFAA198318)
广西壮族自治区南宁市青秀区重点研发计划项目(编号:2021003,2020053)
广西医科大学第一附属医院临床研究攀登计划项目(编号:YYZS2020010)。